Granted Patent
B2
US 12,291,570 · App. 17/285,511 · Granted May 6, 2025
Treatment of metastatic pancreatic adenocarcinoma
Inventors:
Abi Vainstein-Haras (Herzliya, IL); Ella Sorani (Kadima, IL); Irit Gliko-Kabir (Modiln, IL); Osnat Bohana-Kashtan (Tel-Mond, IL); Amnon Peled (Tel-Aviv, IL)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma.
Claims (11)
1. A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 antibody and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma, wherein administering comprises a monotherapy period with said peptide followed by a combination therapy with said peptide, said anti PD-1 antibody and said chemotherapy, wherein said subject is post first-line treatment against said metastatic pancreatic adenocarcinoma, wherein said chemotherapy comprises irinotecan, fluorouracil (5-FU) and leucovorin (LV), wherein said anti-PD-1 antibody is pembrolizumab and wherein said combination therapy with said chemotherapy and said anti PD-1 is initiated on Day 8, and wherein said first-line treatment comprises a gemcitabine-based chemotherapy.
2. The method of claim 1 , wherein said combination therapy is repeated every 2 weeks with said chemotherapy and every 3 weeks with said anti PD-1.
3. The method of claim 1 , wherein said monotherapy is performed on Days 1-5, daily.
4. The method of claim 3 , wherein said treatment further comprises an anti-histamine and optionally analgesics.
5. The method of claim 1 , wherein said combination therapy with said peptide is initiated on Day 10 two times a week on non-consecutive days, 48 hours apart.
6. The method of claim 1 , wherein said chemotherapy is administered intravenously.
7. The method of claim 1 , wherein said irinotecan is liposome-encapsulated.
8. The method of claim 1 , wherein said peptide is administered subcutaneously (SC).
9. The method of claim 1 , wherein said peptide is administered at a dose of 1.25 mg/kg.
10. The method of claim 1 , wherein said anti PD-1 is administered intravenously (IV).
11. The method of claim 1 , wherein said anti PD-1 is administered at a dose of 200 mg.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 21, 2021
From: VAINSTEIN-HARAS, ABI; SORANI, ELLA; GLIKO-KABIR, IRIT; BOHANA-KASHTAN, OSNAT
To: BIOLINERX LTD.
Reel/Frame 057861/0243 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 21, 2021
From: PELED, AMNON
To: BIOKINE THERAPEUTICS LTD.
Reel/Frame 057861/0471 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 21, 2021
From: BIOKINE THERAPEUTICS LTD.
To: BIOLINERX LTD.
Reel/Frame 057862/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 21, 2021
From: BIOLINERX LTD.
To: BIOLINERX LTD.; MERCK SHARP & DOHME CORP.
Reel/Frame 057862/0466 →
Continuity (2)
Provisional Application
62746587
· Oct 17, 2018
References Cited (84)
US 7138488B2
· Fujii
· 2006
[cited by applicant]
US 7423007B2
· Fujii et al.
· 2008
[cited by applicant]
US 7595298B2
· Fujii
· 2009
[cited by applicant]
US 8017585B2
· Fujii et al.
· 2011
[cited by applicant]
US 8410059B2
· Fujii et al.
· 2013
[cited by applicant]
US 8765683B2
· Peled et al.
· 2014
[cited by applicant]
US 9439942B2
· Peled et al.
· 2016
[cited by applicant]
US 20200223924A1
· Stein et al.
· 2020
[cited by applicant]
US 20220072087A1
· Stein et al.
· 2022
[cited by applicant]
US 20230242644A1
· Vainstein-Haras et al.
· 2023
[cited by applicant]
CN 108026173
· 2018
[cited by applicant]
CN 108495629
· 2018
[cited by applicant]
WO WO2013188586
· 2013
[cited by applicant]
WO WO2017034957
· 2016
[cited by examiner]
WO WO2017009842
· 2017
[cited by applicant]
WO WO2017009843
· 2017
[cited by applicant]
WO WO2018083470
· 2018
[cited by applicant]
WO WO2020079692
· 2020
[cited by applicant]
WO WO2020148744
· 2020
[cited by applicant]
WO WO2020148745
· 2020
[cited by applicant]
WO WO2021009761
· 2021
[cited by applicant]
Weiss G et al., Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma, 2017, Investigational New Drugs, 36:96-102 (Year: 2017).
[cited by examiner]
Hadzijusufovic E et al., H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells, 2010, Experimental Hematology, 38:896-907 (Year: 2010).
[cited by examiner]
Gandhi L et al., Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, 2018, NEJM, 378;22 (Year: 2018).
[cited by examiner]
Clinical trial#NCT02826486, 2016, https://clinicaltrials.gov/ct2/show/record/NCT02826486.
[cited by examiner]
Wang-Gillam et. al., Lancet. 387:545-557 (2016) (Year: 2016).
[cited by examiner]
Kim et. al. PLOS Computational Biology. 12(3):1-15. (2016) (Year: 2016).
[cited by examiner]
Deer et. al. Pancreas 39(4).425-435. (2011) (Year: 2011).
[cited by examiner]
Wang et. al. Current Cancer Drug Targets 14:407-417 (2014) (Year: 2014).
[cited by examiner]
BioLineRx Announces Final Results from Phase 2a Combat/Keynote-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC) (2020) (Year: 2020).
[cited by examiner]
Mercadé et. al. (Pancreas 49(1):62-75. (2020)) (Year: 2020).
[cited by examiner]
Petrelli et. al. European Journal of Cancer. 81:174-182 (2017) (Year: 2017).
[cited by examiner]
Wang-Gilliam et. al. (European Journal of Cancer 108:78-87 (2019) (Year: 2019).
[cited by examiner]
Tourneua et. al. JNCI. 101(10):708-720. 2009 (Year: 2009).
[cited by examiner]
Bockorny et. al. Nat Med. 26:878-885 (2020) (Year: 2020).
[cited by examiner]
International Preliminary Report on Patentability Dated Apr. 29, 2021 From the International Bureau of WIPO Re. Application No. PCT/IL2019/051129. (8 Pages).
[cited by applicant]
International Search Report and the Written Opinion Dated Oct. 21, 2020 From the International Searching Authority Re. Application No. PCT/IL2020/050798. (13 Pages).
[cited by applicant]
International Search Report and the Written Opinion Dated Feb. 26, 2020 From the International Searching Authority Re. Application No. PCT/IL2019/051126. (16 Pages).
[cited by applicant]
International Search Report and the Written Opinion Dated Feb. 26, 2020 From the International Searching Authority Re. Application No. PCT/IL2019/051129. (16 Pages).
[cited by applicant]
International Search Report and the Written Opinion Dated Feb. 26, 2020 From the International Searching Authority Re. Application No. PCT/IL2019/051127. (16 Pages).
[cited by applicant]
Beider et al. “Anti-Leukemia and Multiple Myeloma Selective Activity of CXCR4 Antagonist 4F-Benzoyl-TN14003 Involves Apoptotic Death Pathway”, Database BIOSIS [Online], XP002796778, Database Accession No. PREV2010003548…
[cited by applicant]
Beider et al. “Anti-Leukemia and Multiple Myeloma Selective Activity of CXCR4 Antagonist 4F-Benzoyl-TN14003 Involves Apoptotic Death Pathway”, XP882796778, Blood, 114(22): 3857, Nov. 20, 2009.
[cited by applicant]
Gebbia et al. “Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma: A Multicenter Experience of the Gruppo Oncologico Italia Meridionale”, American Jo…
[cited by applicant]
Hidalgo et al. “Evaluation of Pharmacodynamic (PD) Biomarkers in Patients With Metastatic Pancreatic Cancer Treated With BL-8040, A Novel CXCR4 Antagonist”, Journal of Clinical Oncology, 36(5/Suppl.): # 88, Feb. 10, 201…
[cited by applicant]
Kim et al. “Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, Efficacy and Resistance”, XP055659482, Journal of Biomedical Sciences, 6(2:14): 1-9, Feb. 22, 2017.
[cited by applicant]
Mori et al. “Involvement of Stromal Cell-Derived Factor 1 and CXCR4 Receptor System in Pancreatic Cancer”, Gastroenterology, XP009021758, 122(4/Suppl.1): A490, Abstract # T1608, Apr. 2002.
[cited by applicant]
Smith et al. “Nivolumab for the Treatment of Colorectal Cancer”,Expert Review of Anticancer Therapy, 18(7): 611-618, Jun. 11, 2018.
[cited by applicant]
ClinicalTrials “Chemo4METPANC Combination Chemotherapy in Patients With Pancreatic Adenocarcinoma”, History of Changes for Study: NCT04543071, Nov. 7, 2022.
[cited by applicant]
International Preliminary Report on Patentability Dated Jul. 29, 2021 From the International Bureau of WIPO Re. Application No. PCT/IL2019/051127. (8 Pages).
[cited by applicant]
Office Action Dated Jul. 20, 2023 From the Israel Patent Office Re. Application No. 282317. (4 Pages).
[cited by applicant]
Notification of Office Action and Search Report Dated Dec. 1, 2023 From the National Intellectual Property Administration of the People's Republic of China Re. Application No. 201980081755.X. (6 Pages).
[cited by applicant]
Notice of Reason(s) for Rejection Dated Sep. 5, 2023 From the Japan Patent Office Re. Application No. 2021-519139. (3 pages).
[cited by applicant]
Weiss et al. “A Phase Ib Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)”, British Journal of Cancer, 117(1): 33-40, 2017.
[cited by applicant]
English Translation Dated Dec. 12, 2023 of Notification of Office Action and Search Report Dated Dec. 1, 2023 From the National Intellectual Property Administration of the People's Republic of China Re. Application No. …
[cited by applicant]
Translation Dated Sep. 19, 2023 of Notice of Reason(s) for Rejection Dated Sep. 5, 2023 From the Japan Patent Office Re. Application No. 2021-519139. (4 pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Mar. 7, 2024 From the European Patent Office Re. Application No. 19797388.6 (6 Pages).
[cited by applicant]
Restriction Official Action Dated Mar. 1, 2024 From the US Patent and Trademark Office Re. U.S. Appl. No. 17/422,786. (8 pages).
[cited by applicant]
Translation Dated Mar. 1, 2024 of Notice of Reason(s) for Rejection Dated Feb. 20, 2024 From the Japan Patent Office Re. Application No. 2021-519139. (1 page).
[cited by applicant]
Official Action Dated Apr. 30, 2024 from the US Patent and Trademark Office Re. U.S. Appl. No. 7/422,786. (86 pages).
[cited by applicant]
Official Action Dated Mar. 8, 2024 From the US Patent and Trademark Office Re. U.S. Appl. No. 18/109,281. (36 pages).
[cited by applicant]
Berlin et al. “Editorial: Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Conference”, Annals of Surgical Oncology, 16: 1757-1759, 2009.
[cited by applicant]
Notice of Reason(s) for Rejection Dated Feb. 20, 2024 From the Japan Patent Office Re. Application No. 2021-519139. (3 pages).
[cited by applicant]
Examination Report Dated Nov. 7, 2024 From the Australian Government, IP Australia Re. Application No. 2019360044. (4 Pages).
[cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated May 22, 2024 From the European Patent Office Re. Application No. 19797831.5. (5 Pages).
[cited by applicant]
Examination Report Dated Jul. 22, 2024 From the Australian Government, IP Australia Re. Application No. 2019360044. (5 Pages).
[cited by applicant]
Official Action Dated Jun. 18, 2024 from the US Patent and Trademark Office Re. U.S. Appl. No. 18/109,281. (29 pages).
[cited by applicant]
Official Action Dated Feb. 26, 2025 from the US Patent and Trademark Office Re. U.S. Appl. No. 18/109,281. (24 pages).
[cited by applicant]
Feig et al. “Targeting CXCL12 from FAP-expressing Carcinoma-associated Fibroblasts Synergizes with Anti-PD-L1 Immunotherapy in Pancreatic Cancer”, Research Article, Biological Sciences, PNAS, 110 (50) 20212-20217, Nov. …
[cited by applicant]
Manji et al. “CheMo4METPANC: A Randomized Phase 2 Study with Combination Chemotherapy (Gemcitabine and Nab-paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (Motixafortide), and Immune Checkpoint Blockade (Cemip…
[cited by applicant]